

Customer No.: 20462
Confirmation No. 6175

Attorney Docket No. PB60024

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Irving, et al.	Date:	April 21, 2010
Serial No.:	10/550,363	Group Art Unit No.:	1615
Filed:	April 15, 2007	Examiner:	Kolker, Daniel
For:	Therapeutical Use of Anit-Myelin Associated Glcoprotein (MAG)		
Antibodies			

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Filing of an Information Disclosure Statement under 37 C.F.R. §1.97(c) and
Statement under 37 C.F.R. §1.97(e)

Information Disclosure Statement. The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of each are enclosed, except U.S. patent documents, and those documents already part of the filewrapper. This information disclosure statement is being filed with a Statement as specified in 37 C.F.R. §1.97(e) and without any fee in accordance with the provisions of 37 C.F.R. §1.97(c)(1), and before the mailing a Final Action under 37 CFR §1.113, or a Notice of Allowance under 37 CFR §1.311 as specified in 37 C.F.R. §1.97(c).

Statement Under 37 C.F.R. §1.97(e) The undersigned hereby states:


☒ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. §1.97(e)(1).

or

☐ that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Note: M.P.E.P. § 609.04(b)(V) – An information disclosure statement may include two lists and two statements,, in situations where some of the information listed was cited in a communication from a foreign patent office not more than 3 months prior to filing the statement and some was not, but was not known more than 3 months prior to filing the statement.

Respectfully submitted,



Jason C. Fedon
Attorney for Applicants
Registration No. 48,138

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6150
Facsimile (610) 270-5090